Cogent Biosciences, Inc. (COGT) News
Filter COGT News Items
COGT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COGT News Highlights
- For COGT, its 30 day story count is now at 3.
- Over the past 4 days, the trend for COGT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MC, DEC and MG are the most mentioned tickers in articles about COGT.
Latest COGT News From Around the Web
Below are the latest news stories about COGENT BIOSCIENCES INC that investors may wish to consider to help them evaluate COGT as an investment opportunity.
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at least 50% improvement in key biomarkers of disease burden: serum tryptase reduction (94%), KIT D816V VAF reduction (93%), and bone marrow mast cell burden (97%) Encouraging safety and tolerability profile with no related cognitive impairment or bleeding events reported Cogent to host investor webcast to |
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, including serum tryptase, KIT D816V VAF, and mast cell burden; Placebo patients, after cross-over to bezuclastinib, also demonstrated rapid symptomatic improvement, with 75% median best improvement on MC-QoL, and 67% of pat |
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer SymposiumNovel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies Novel, H1047R mutant-selective PI3Kα inhibitor, disclosed as third Cogent discovery stage program, demonstrates high clinical target engagement without metabolic dysfunction commonly associated with molecules in the class WALTHAM, Mass. and BOULDER, Colo., Dec. 07, 2023 (GLOBE NEWSWIRE |
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM) also to be reviewed WALTHAM, Mass. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its invest |
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer SymposiumWALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry B. González Convention Center in San Antonio, Texas. Poster DetailsThe posters will be available on the ‘Posters and Publications’ page of |
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsSUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2 expected to begin in 1H 2024 at over 50 sites globally 33% ORR and >14 months median duration of treatment for 2nd-line GIST patients from updated PEAK lead-in data presented at 2023 CTOS Annual Meeting Ended Q3 2023 with $312.8 million, providing cash runway into 2026 WALTHAM, Mass. and BOULDER, Colo., |
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and initiation of clinical trial planned in 2H 2024 - WALTHAM, Mass. and BOULDER, Colo., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, announced updated preclinical data from the Company’s |
After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gainKey Insights Given the large stake in the stock by institutions, Cogent Biosciences' stock price might be vulnerable to... |
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsInitial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on track Selective FGFR2 inhibitor nominated as first Cogent-discovered clinical candidate; additional preclinical data planned for presentation in 2H 2023 Ended 2Q 2023 with $350.9 million, sufficient to fund operations into 2026 WALTHAM, Mass. and BOULDER, Colo., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cogent |